Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary - 14/12/17
Doi : 10.1016/j.jaad.2017.02.016
Yuan Yu Michael Huang, MD ⁎ 
, Sylvia Hsu, MD
, Sylvia Hsu, MD Department of Dermatology, Baylor College of Medicine, Houston, Texas
∗Correspondence to: Yuan Yu Michael Huang, MD, Department of Dermatology, Baylor College of Medicine, 1977 Butler Blvd, Houston, TX 77030Department of DermatologyBaylor College of Medicine1977 Butler BlvdHoustonTX77030
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Disclosure: Dr Hsu is an advisory board member for AbbVie, Amgen, Janssen, Eli Lilly, Novartis, and Valeant. She receives honoraria from these companies. Dr Hsu is also an investigator for Centocor and receives fees paid to her associated institution. Dr Huang has no conflicts of interest to declare. |
© 2017
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 76 - N° 6
P. e221 - juin 2017 Retour au numéro
Article précédent
- Reply: Female sexual assault victims and the skin examination
- Jane M. Grant-Kels
- Are normal serum levels of insulin-like growth factor-1 clinically relevant in acne?
- Clio Dessinioti, Eftychia Koukkou, George Kontochristopoulos, Christina Antoniou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?